The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction
Medicina · 2026
DOI: 10.3390/medicina62050870 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicina, 2026. Verfasst von Rachel Su Min Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Heart Failure, Stroke Volume, Receptors, Gastrointestinal Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Glucagon-like Peptide 1 (GLP-1)-based medications have been extensively studied for the management of type 2 diabetes, obesity, chronic kidney disease, and atherosclerotic cardiovascular disease. More recently, their potential role in preventing and treating heart failure has gained increasing attention. Given the strong pathophysiological links among diabetes, obesity, and heart failure, GLP-1-based medications represent a promising therapeutic option to improve morbidity and mortality across these interconnected conditions. In this review, we summarise and discuss recent studies involving GLP-1-based medications that have reported on HF-related outcomes. There is increasing evidence that these medications have beneficial effects on HF outcomes in patients with heart failure with preserved ejection fraction and possibly in those with mildly reduced ejection fraction. The usefulness of GLP-1-based medications in reduced ejection fraction HF remains to be defined.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia.
- Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Melbourne, VIC 3084, Australia.
- Department of Cardiology, Austin Health, Heidelberg, Melbourne, VIC 3084, Australia.
- Advara Heart Care, Mulgrave Private Hospital, Mulgrave, Melbourne, VIC 3170, Australia.
- Department of Cardiometabolic Imaging, Baker Heart and Diabetes Institute, University of Melbourne, Melbourne, VIC 3004, Australia.
- Department of Cardiology, St Vincent's Hospital Melbourne, Fitzroy, Melbourne, VIC 3065, Australia.
ORCID-Profile: Rachel Su Min Lee, Piyush M Srivastava, Eylem Levelt, Angeline S Leet, Richard J MacIsaac
Zitieren
APA
Lee, R. S. M., Seah, J. M., Baqar, S., Srivastava, P. M., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026). The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction. Medicina. https://doi.org/10.3390/medicina62050870
Vancouver
Lee RSM, Seah JM, Baqar S, Srivastava PM, Levelt E, Leet AS, et al. The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction. Medicina. 2026. doi:10.3390/medicina62050870
BibTeX
@article{Lee2026,
author = {Lee, Rachel Su Min and Seah, Jas-Mine and Baqar, Sara and Srivastava, Piyush M and Levelt, Eylem and Leet, Angeline S and MacIsaac, Andrew I and Ekinci, Elif I and MacIsaac, Richard J},
title = {The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction},
journal = {Medicina},
year = {2026},
doi = {10.3390/medicina62050870}
}
EUVIMED